A randomized, double‐blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation
- 12 July 2007
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 13 (5), 527-532
- https://doi.org/10.1111/j.1365-2516.2007.01516.x
Abstract
Recombinant activated factor VIIa (rFVIIa) is a well-established treatment for bleeding episodes in patients with congenital or acquired haemophilia A or B with inhibitors to factors VIII and IX and patients with FVII deficiency. The aim of this trial was to demonstrate bioequivalence between the currently marketed (rFVIIa/NovoSeven) and a new rFVIIa formulation (VII25) stable at up to 25 degrees C. Furthermore, short-term safety and tolerability of VII25 and pharmacokinetics of both formulations were investigated. In this single-centre, randomized, double-blind, two-way cross-over trial, healthy male subjects received one intravenous bolus injection of rFVIIa and one of VII25, both at 90 microg kg(-1), in a randomized order 2-3 weeks apart. Mean VII25/rFVIIa ratio for area under the plasma activity-time curve from time 0 to last quantifiable activity (primary bioequivalence endpoint), was 0.93, 90% confidence interval (CI) (0.89-0.96), within the predefined bioequivalence range (0.80-1.25). Secondary pharmacokinetic parameters were comparable between formulations. No serious adverse events were observed. Six mild or moderate treatment-emergent adverse events were reported in five subjects. Coagulation-related parameter profiles were similar between rFVIIa and VII25. No clinically abnormal changes were observed for laboratory parameters and no subjects developed FVIIa antibodies. This trial demonstrated bioequivalence between the currently available rFVIIa and VII25 stable at up to 25 degrees C. VII25's 'user-friendly' formulation removes the inconvenience of storing/transporting at 2-8 degrees C, and as the drug substance is the same, the activity and safety established for rFVIIa is maintained.Keywords
This publication has 10 references indexed in Scilit:
- Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profileTransfusion, 2006
- Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitorsJournal of Thrombosis and Haemostasis, 2004
- A Cell-based Model of HemostasisThrombosis and Haemostasis, 2001
- Pharmacokinetics of Coagulation FactorsClinical Pharmacokinetics, 2001
- The Continuous Infusion of Recombinant Activated Factor VIIa (rFVIIa) in Patients with Factor VIII Inhibitors Activates the Coagulation and Fibrinolytic Systems without Clinical ComplicationsThrombosis Research, 2000
- Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing SurgeryThrombosis and Haemostasis, 1998
- Platelet activity of high‐dose factor VIIa is independent of tissue factorBritish Journal of Haematology, 1997
- Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activationBlood, 1993
- Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation.Proceedings of the National Academy of Sciences of the United States of America, 1988
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987